Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of 82.26 HKD [7][11]. Core Insights - The company is expected to achieve significant growth in 2025, with revenue, net profit, and adjusted net profit projected at 5.944 billion, 1.480 billion, and 1.559 billion RMB respectively, representing year-on-year increases of 46.69%, 38.41%, and 69.93% [1][10]. - The company has a strong order pipeline, with new contracts signed in 2025 amounting to 1.33 billion USD, a 41% increase year-on-year, and a backlog of 1.49 billion USD, up 50% year-on-year [2]. - The company is expanding its production capacity through both self-built facilities and acquisitions, enhancing its global leadership position in the industry [3]. Summary by Sections Financial Performance - In 2025, the company achieved a gross margin of 36.0%, an increase of 5.4 percentage points year-on-year, indicating strong operational efficiency [4]. - The company’s sales, management, and R&D expenses for 2025 were 1.09 billion, 2.25 billion, and 1.47 billion RMB respectively, with corresponding expense ratios of 1.8%, 3.8%, and 2.5% [4]. Capacity Expansion - The company is set to double its DP capacity by 2029, with several new production lines expected to come online between 2026 and 2028 [3]. - The acquisition of Dongyao Pharmaceuticals adds significant production capabilities, including two antibody production lines and three ADC production workshops [3]. Profitability Forecast - Adjusted net profit forecasts for 2026 and 2027 have been revised to 2.11 billion and 2.87 billion RMB, reflecting a compound annual growth rate (CAGR) of 35% from 2025 to 2027 [5][11]. - The expected earnings per share (EPS) for 2026 and 2027 are projected at 1.68 and 2.28 RMB respectively [10][11].
药明合联：2025年业绩高增，龙头地位稳固-20260325